2',3'-Dideoxyinosine (ddIno) is effective against human immunodeficiency virus (HIV) in vitro. It is currently in Phase I clinical trials. The chronicity of HIV infection requires continuous therapy to maintain an effective inhibitory drug concentration in plasma and cerebrospinal fluid. Pharmacokinetic data are needed to ascertain that the doses given to patients will produce the therapeutic and nontoxic drug concentrations in blood and cerebrospinal fluid. However, there are limited pharmacokinetic data on ddIno. IN the few patients who received oral doses, ddIno has a systemic bioavailability of between 6 to 50%. This large intersubject variation is likely to produce different pharmacologic effects and responses in patients. The low bioavailability indicates that more than 50% of the dose is lost prior to reaching the systemic circulation. The cause of this extensive loss of the dose prior to reaching the systemic circulation is unknown. The loss could be due to presystemic metabolism in the gastrointestinal tract and liver, incomplete absorption and/or degradation in the stomach. The long range goal of our research plan is to improve the bioavailability and systemic delivery of ddIno. An increased bioavailability towards unity will reduce intersubject variability and enhance drug activity. The immediate objectives are to characterize the pharmacokinetics of ddIno, its disposition after oral administration and the cause of its low and variable oral bioavailability, and to explore different nonparenteral administration routes. These data will help to understand the absorption, distribution and metabolism of ddIno, and to define strategies for a better drug delivery. ddIno may be used in combination with another potent anti-HIV compound, 3'-azido- 3'deoxythymidine (AZT), which can compete for the absorption and metabolism of ddIno. We will examine potential pharmacokinetic interactions between ddIno and AZT. Rats will be used for these studies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI028757-02
Application #
3143293
Study Section
Special Emphasis Panel (ARR (V1))
Project Start
1989-09-01
Project End
1992-08-31
Budget Start
1990-09-01
Budget End
1991-08-31
Support Year
2
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Silberman, Jeffrey D; Simpson, Alastair G B; Kulda, Jaroslav et al. (2002) Retortamonad flagellates are closely related to diplomonads--implications for the history of mitochondrial function in eukaryote evolution. Mol Biol Evol 19:777-86
Sul, D; Kaneshiro, E S (2001) Pneumocystis carinii f. sp. carinii synthesizes de novo four homologs of ubiquinone. J Eukaryot Microbiol 48:182-7
Kang, H J; Wientjes, M G; Au, J L (1997) Physiologically based pharmacokinetic models of 2',3'-dideoxyinosine. Pharm Res 14:337-44
Yeh, T K; Kang, H J; Wientjes, M G et al. (1996) Pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and pentamidine in rats. Pharm Res 13:628-32
Gao, X; Wientjes, M G; Au, J L (1995) Use of drug kinetics in dermis to predict in vivo blood concentration after topical application. Pharm Res 12:2012-7
Gao, X; Wientjes, M G; Au, J L (1995) Extensive absorption of 2',3'-dideoxyinosine by intratracheal administration in rats. Pharm Res 12:1901-6
Gupta, E; Wientjes, M G; Au, J L (1995) Penetration kinetics of 2',3'-dideoxyinosine in dermis is described by the distributed model. Pharm Res 12:108-12
Mukherji, E; Millenbaugh, N J; Au, J L (1994) Percutaneous absorption of 2',3'-dideoxyinosine in rats. Pharm Res 11:809-15
Mukherji, E; Au, J L; Mathes, L E (1994) Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells. Antimicrob Agents Chemother 38:1573-9
Kang, H J; Wientjes, M G; Au, J L (1994) Tissue pharmacokinetics of 2',3'-dideoxyinosine in rats. Biochem Pharmacol 48:2109-16

Showing the most recent 10 out of 17 publications